Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tradipitant in treatment-resistant pruritus associated with atopic dermatitis
NCT02651714Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jan 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Tradipitant with Placebo (2 arms). Primary endpoint: Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS). Started Jan 2016; status: completed.
02
Drugs
tradipitant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02651714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651714.